IRIS
CONSOLARO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.645
Totale 11.645
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.645
Totale 11.645
Salva come PNG Salva come JPEG
Città #
Genova 8.887
Rapallo 1.366
Genoa 1.059
Vado Ligure 302
Bordighera 31
Totale 11.645
Salva come PNG Salva come JPEG
Nome #
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 153
Juvenile Idiopathic Arthritis: Diagnosis and Treatment 153
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 145
The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 142
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 138
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 127
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 124
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 123
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 120
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 119
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases 118
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 118
Advances in biomarkers for paediatric rheumatic diseases 117
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 116
The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 116
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 116
Development and testing of reduced joint counts in juvenile idiopathic arthritis. 115
Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas - Key to understanding etiology and genetic factors? 115
TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis 115
The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 115
The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 115
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 115
The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 114
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 114
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 113
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 113
The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 113
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 112
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 112
It is worth including assessment of disease activity state in juvenile arthritis clinical trials. 111
Clinical outcome measures in juvenile idiopathic arthritis 111
The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 111
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 110
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 110
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 110
Glucocorticoids in juvenile idiopathic arthritis. 108
The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 107
The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 107
The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 107
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis 107
Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016 107
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 107
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 106
The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 106
The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 106
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 105
The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 105
The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 105
The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 105
The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 104
The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 104
The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 103
Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis 102
The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 102
Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. 101
The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 101
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 100
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 100
Recent therapeutic advances in juvenile idiopathic arthritis 99
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 99
Prevalence of overweight and obesity in 2- to 6-year-old Italian children 98
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 98
The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 98
The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 97
The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 97
The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 97
Defining criteria for disease activity States in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. 96
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 96
The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 96
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 96
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 96
The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 95
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 95
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 95
The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 94
Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis 93
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop 93
A child with a novel ACAN missense variant mimicking a septic arthritis 93
The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 92
The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 92
Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. 92
Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. 91
Paediatric rheumatology: Juvenile idiopathic arthritis--are biologic agents effective for pain? 91
Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era 90
Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). 89
The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 87
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis 86
The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 85
Optimisation of disease assessments in juvenile idiopathic arthritis. 83
The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 83
The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 82
The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 82
The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 81
Treating juvenile idiopathic arthritis to target: Recommendations of an international task force 81
Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. 80
Defining criteria for disease activity states in juvenile idiopathic arthritis 79
Ghrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children 79
Glucocorticoids in paediatric rheumatology 78
Totale 10.440
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.833
article - articoli 39.833
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.666
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.107 0 0 94 256 309 588 719 594 513 567 340 127
2020/20211.389 68 157 71 150 76 70 137 135 71 178 70 206
2021/20221.488 72 59 122 119 55 123 61 326 125 175 63 188
2022/20231.632 147 147 21 144 251 274 9 159 276 14 165 25
2023/2024822 35 113 35 110 71 73 89 46 41 35 48 126
2024/2025337 78 217 42 0 0 0 0 0 0 0 0 0
Totale 12.148